Physician
G&S Medical Associates LLC
G&S Medical Associates LLC was paid $17.08M by Medicaid between Jan 2018 and Dec 2024, across 162 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 42% of everything it billed.
33Billing provider infoG&S MEDICAL ASSOCIATES LLC
PATERSON, NJ 07514
PATERSON, NJ 07514
33aNPI1982982336assigned 08/02/2011
33bProvider typePsychiatry Physician
28Total paid$17.08M
24GClaims981,876
24DCodes billed162
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatry Physician providers in New Jersey
Rank by total paid#1 of 130
Median peer was paid$19K
This provider vs. median919×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,792 | $823K | |
| 2019 | 85,658 | $1.39M | |
| 2020 | 84,344 | $1.84M | |
| 2021 | 148,803 | $3.30M | |
| 2022 | 235,298 | $4.35M | |
| 2023 | 212,019 | $3.09M | |
| 2024incomplete | 170,962 | $2.29M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 42% | 165,859 | 136,205 | $7.18M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 8.2% | 49,855 | 42,596 | $1.41M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.7% | 19,214 | 15,330 | $971K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 5.3% | 31,449 | 26,333 | $903K |
| 99490 | Ccm add 20min | 3.8% | 34,048 | 33,257 | $653K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.7% | 14,567 | 12,064 | $641K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.2% | 43,854 | 38,217 | $548K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 2.8% | 5,934 | 5,800 | $485K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.3% | 6,755 | 6,453 | $388K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.1% | 6,137 | 5,874 | $358K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.9% | 19,898 | 15,871 | $323K |
| 99442 | 1.8% | 11,063 | 9,726 | $304K |
150 more codes
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 1.6% | 3,523 | $267K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.2% | 8,097 | $208K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,330 | $144K |
| 90674 | <1% | 6,219 | $112K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 25,702 | $109K |
| 92546 | <1% | 2,421 | $97K | |
| 92540 | <1% | 2,367 | $90K | |
| 80061 | Lipid panel | <1% | 13,760 | $82K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,365 | $79K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 2,537 | $79K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 7,072 | $76K |
| 94729 | <1% | 2,478 | $68K | |
| 94060 | <1% | 2,471 | $66K | |
| 99408 | <1% | 8,096 | $66K | |
| 80050 | General health panel | <1% | 3,682 | $63K |
| 99401 | <1% | 2,521 | $60K | |
| 93000 | <1% | 6,238 | $58K | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 1,602 | $56K |
| 93923 | <1% | 1,070 | $54K | |
| 80053 | Comprehensive metabolic panel | <1% | 14,903 | $54K |
| 80305 | <1% | 8,601 | $53K | |
| 94727 | <1% | 2,482 | $52K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 905 | $47K |
| 82607 | <1% | 8,000 | $43K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,721 | $43K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,388 | $42K |
| 82948 | <1% | 36,870 | $42K | |
| 95886 | <1% | 498 | $39K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 30,180 | $38K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 24,088 | $38K |
| 92576 | <1% | 1,965 | $34K | |
| 93922 | <1% | 1,003 | $34K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 2,188 | $33K |
| 82746 | <1% | 6,486 | $32K | |
| G0445 | High intensity behavioral counseling to prevent sexually transmitted infection; face-to-face, individual, includes: education, skills training and guidance on how to change sexual behavior; performed semi-annually, 30 minutes | <1% | 1,781 | $28K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,734 | $26K |
| 95912 | <1% | 233 | $24K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 28,628 | $23K |
| 90688 | <1% | 1,896 | $23K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 237 | $21K |
| 95911 | <1% | 212 | $19K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 354 | $18K |
| 99343 | <1% | 68 | $16K | |
| 81003 | <1% | 15,316 | $15K | |
| 92250 | <1% | 817 | $15K | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 521 | $15K |
| 99397 | <1% | 337 | $14K | |
| 84153 | <1% | 2,069 | $13K | |
| 99385 | <1% | 180 | $13K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 9,344 | $11K |
| 96160 | <1% | 6,135 | $11K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 248 | $10K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,272 | $10K |
| 11721 | <1% | 855 | $9K | |
| 92547 | <1% | 2,362 | $9K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,100 | $7K |
| 83735 | <1% | 2,767 | $7K | |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 1,171 | $6K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 137 | $6K |
| 86769 | <1% | 172 | $5K | |
| 83540 | <1% | 2,346 | $5K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 507 | $5K |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 655 | $5K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 21 | $4K |
| 84403 | <1% | 439 | $4K | |
| 99349 | <1% | 409 | $3K | |
| H0006 | Alcohol and/or drug services; case management | <1% | 108 | $3K |
| 84550 | <1% | 1,999 | $3K | |
| 11056 | <1% | 263 | $3K | |
| 82962 | <1% | 4,250 | $3K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 54 | $3K |
| 82043 | <1% | 3,726 | $3K | |
| 82570 | <1% | 2,990 | $3K | |
| S9470 | Nutritional counseling, dietitian visit | <1% | 190 | $3K |
| G0008 | Administration of influenza virus vaccine | <1% | 829 | $2K |
| 99386 | <1% | 27 | $2K | |
| 76872 | <1% | 45 | $2K | |
| 84156 | <1% | 2,081 | $2K | |
| 93978 | <1% | 84 | $2K | |
| 86328 | <1% | 56 | $2K | |
| 96138 | <1% | 420 | $2K | |
| 96132 | <1% | 174 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 105 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 105 | $2K |
| 86580 | <1% | 252 | $1K | |
| 81002 | <1% | 1,621 | $1K | |
| 93880 | <1% | 61 | $1K | |
| 95923 | <1% | 32 | $1K | |
| 92228 | <1% | 175 | $1K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 134 | $987.23 |
| 90736 | <1% | 15 | $952.03 | |
| 95921 | <1% | 32 | $828.81 | |
| 95885 | <1% | 12 | $690.79 | |
| 86592 | <1% | 560 | $648.70 | |
| 99000 | <1% | 585 | $484.76 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 742 | $426.64 |
| 76770 | <1% | 13 | $356.56 | |
| 76857 | <1% | 20 | $339.46 | |
| 82270 | <1% | 292 | $324.48 | |
| 99307 | <1% | 70 | $318.48 | |
| 99348 | <1% | 16 | $264.85 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 22 | $237.62 |
| 90756 | <1% | 14 | $210.18 | |
| 90653 | <1% | 13 | $171.96 | |
| 90656 | <1% | 12 | $168.65 | |
| 99072 | <1% | 4,500 | $141.00 | |
| 99406 | <1% | 13 | $132.83 | |
| 99453 | <1% | 12 | $132.73 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 12 | $124.20 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 118 | $97.24 |
| 3080F | <1% | 7,774 | $49.00 | |
| 3008F | <1% | 9,559 | $40.00 | |
| 3078F | <1% | 39,167 | $22.00 | |
| 3074F | <1% | 36,021 | $18.00 | |
| 3077F | <1% | 15,891 | $12.00 | |
| 92700 | <1% | 21 | $10.00 | |
| 3079F | <1% | 26,036 | $10.00 | |
| 3075F | <1% | 21,189 | $9.00 | |
| 2022F | <1% | 127 | $7.00 | |
| 1170F | <1% | 1,566 | $6.00 | |
| 1160F | <1% | 1,899 | $2.00 | |
| 3061F | <1% | 1,058 | $1.00 | |
| 1159F | <1% | 1,529 | $1.00 | |
| 1126F | <1% | 285 | $0.01 | |
| 1125F | 0% | 1,670 | $0.00 | |
| 3060F | 0% | 30 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 7,902 | $0.00 |
| G8418 | Bmi is documented below normal parameters and a follow-up plan is documented | 0% | 423 | $0.00 |
| 1157F | 0% | 1,224 | $0.00 | |
| 2000F | 0% | 2,938 | $0.00 | |
| 3014F | 0% | 818 | $0.00 | |
| 3072F | 0% | 218 | $0.00 | |
| 80069 | 0% | 835 | $0.00 | |
| 3044F | 0% | 1,523 | $0.00 | |
| G8419 | Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 0% | 13 | $0.00 |
| 81528 | Oncology (colorectal) screening, quantitative real-time target and signal amplification | 0% | 41 | $0.00 |
| 2023F | 0% | 16 | $0.00 | |
| 3052F | 0% | 24 | $0.00 | |
| 81005 | 0% | 41 | $0.00 | |
| 3048F | 0% | 12 | $0.00 | |
| 1158F | 0% | 637 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 6,804 | $0.00 |
| 3051F | 0% | 292 | $0.00 | |
| 3046F | 0% | 119 | $0.00 | |
| 3288F | 0% | 2,052 | $0.00 | |
| 3015F | 0% | 162 | $0.00 | |
| 77061 | 0% | 87 | $0.00 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 0% | 14 | $0.00 |
| 82565 | 0% | 51 | $0.00 | |
| 1100F | 0% | 169 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHASSANIEN, GAMMAL (PRACTICE OWNER)